This restoration of PARP inhibitor sensitivity is attributed to the ability of 5hmC and VitC to trap PARP1 and increase DNA damage via the formation of replication gaps; therefore, this treatment can be beneficial for patients with cancers resistant to current FDA-approved PARP inhibitor therapies. The gene discussed is PARP1; the disease is cancer.